NKGen Biotech, Inc.

NKGen Biotech, Inc. (Nasdaq: NKGN) is a clinical-stage biopharmaceutical company developing natural killer cell therapies, with a lead program targeting neurodegenerative indications including Alzheimer's disease. The company entered public markets through a business combination with Graf Acquisition Corp. IV, a blank-check vehicle sponsored by Graf Holdings that completed its IPO in 2021 with a focus on the healthcare and life sciences sector. The de-SPAC transaction closed in September 2023, listing the combined entity on Nasdaq under the NKGN ticker. The company submitted an 8-K filing with the SEC on September 9, 2025. Sign up at SpacDesk for full filing timelines, sponsor profiles, and deal analytics on NKGN and hundreds of other SPAC transactions.